As an investor in Neuren since 2013 I am doing pretty well. It...

As an investor in Neuren since 2013 I am doing pretty well. It has been a long but overall exciting ride.

My main interest now is the combined results of the upcoming three 2591 P2 trials.

If overall success is achieved that will be good enough for me and the end of concentration on profit. My over-riding hope is that thereafter 2591 would progess along a pathway which maximises medical benefit over profit, whatever that pathway may be.

Brickbats to those who have ridiculed the idea that investing is purely about maximising the almighty dollar. We are not all the same in that respect.